ENMD-2076 regulatory update

FDA granted Orphan Drug designation to EntreMed's ENMD-2076 to treat acute myelogenous leukemia (AML). The oral dual-acting Aurora kinase A ( AURKA; Aurora-A) and tyrosine kinase inhibitor is in Pha...